Celiac disease screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]

Overview

Screening with tissue transglutaminase (tTG) IgA test is recommended for symptomatic high risk celiac disease patients.

Screening

Screening in asymptomatic celiac disease patients is not recommended.^[1]
Screening is recommended for symptomatic and high risk patients with positive family history in first and second degree relatives as well as in patients with other autoimmune diseases such as, type 1 diabetes mellitus, inflammatory luminal gastrointestinal disorders, Down syndrome, Turner syndrome, IgA deficiency, and IgA nephropathy.^[1]
Screening method for celiac disease is tissue transglutaminase (tTG) IgA test.

References

↑ ^1.0 ^1.1 Chou R, Bougatsos C, Blazina I, Mackey K, Grusing S, Selph S (2017). “Screening for Celiac Disease: Evidence Report and Systematic Review for the US Preventive Services Task Force”. JAMA. 317 (12): 1258–1268. doi:10.1001/jama.2016.10395. PMID 28350935.

Overview